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1. Introduction 
We have suggested that the structurally related 
intestinal peptides vasoactive intestinal peptide (VIP) 
and secretin were effective on some of their target 
tissues through discrete binding sites coupled to a 
membrane-bound adenylate cyclase (EC 6.4.1 .I) 
[l-3]. In [4], we have shown that a novel peptide, 
the ‘porcine peptide having N-terminal histidine and 
C-terminal isoleucine amide’ (PHI) (formerly named 
PIHIA [4]), isolated from the porcine duodenum 
according to a specific chemical feature [5,6], pos- 
sesses VIP-like activities. We have investigated in vitro 
the effect of PHI on cellular and plasma membrane 
preparations from the rat that are known to display 
either VIP-receptors (liver [l] and intestine [2]), 
secretin-receptors (stomach [3]), or both (fat [ 1,7]). 
The interest of this work was further supported by 
the recent observation that PHI possesses tructural 
similarities with the peptides of the glucagon-VIP- 
secretin family [6]. 
We show here that, when tested on the production 
of 3’,5’-cyclic adenosine monophosphate (cyclic 
AMP), PHI was 20-40% as potent as VIP in tissue 
preparations that are primarily sensitive to VIP and 
2-S% as potent as secretin in a preparation in which 
the latter peptide displays the predominant effect. 
In all cases, the effectiveness of PHI was correlated 
to the presence of either or both VIP (and secretin) 
receptors. 
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2. Materials and methods 
2.1. Peptides 
All peptides were of porcine origin. PHI was iso- 
lated as in [5,6]. The samples used were essentially 
free of foreign protein material, as attested by chemi- 
cal analysis; of particular interest was the absence of 
any detectable amount of VIP or secretin; it must 
also be noticed that: (i) PHI did not display any mea- 
surable interaction with labeled glucagon in its bind- 
ing to hepatic receptors or to several anti-glucagon 
antibodies; (ii) the cross-reaction of PHI in VIP- 
radioimmunoassay [8] was 0.02%. 
VIP was the natural peptide isolated as in [9]. 
Secretin was the synthetic peptide generously sup- 
plied by Professor E. Wiinsch (Abteilung fiir Peptid- 
chemie, Martinsried). VIP and PHI were labeled with 
“‘1 at specific radioactivities ranging from 150-300 
Ci/g (i.e., 0.3-0.6 atom iodine/molecule) using tech- 
niques in [l,lO]. 
2.2. Experimental procedures 
All tissues were obtained from Wistar rats. Binding 
studies were conducted with liver [ 1 l] and intestinal 
epithelial cell membranes [ 121 according to [ 1,101. 
Intestinal epithelial cells [2], epididymal fat cells 
[ 1,7] and gastric glands from the fundus [3] were 
isolated and incubated as described. The cyclic AMP 
production was measured by radioimmunoassay 
[ 13,141 either directly in fat cells [ 1,7] or after 
succinylation [ 151 in intestinal cells or gastric glands 
[2,3], to increase the sensitivity of the assay procedure. 
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3. Results 
3.1. Binding experimen ts 
PHI was extremely effective in inhibiting the bind- 
ing of [1251]VIP to its receptors present either in liver 
membranes (fig.1, upper left) or in intestinal epithe- 
lial cell membranes (fig.1, upper right). In both cases, 
the potency of PHI, estimated in the experimental 
conditions used at concentrations of peptides that 
produced half-maximal inhibition of the binding, was 
-2O-25% of that of VIP. It must be noticed that 
this apparent affinity of PHI for the VIP-receptors 
is much higher than that of secretin, -1% [ 1,16,17], 
the only natural peptide hitherto known to display a 
cross-reaction with the VIP-receptors. When the same 
type of experiment was performed using [ 12sI]PHI 
instead of [ ‘2sl]VIP, a similar pattern was observed: 
PHI was less potent than VIP in inhibiting the bind- 
ing of [ ‘251]PHI to liver (tig.1, lower left) or intes- 
tinal (fig.1, lower right) membranes. The potency of 
PHI relative to that of VIP observed under these con- 
ditions (-20% and 10% in liver and intestinal mem- 
branes, respectively) was similar to that observed 
when VIP was used as the tracer (fig.1, upper panels). 
This clearly shows that these preparations did not 
contain ‘PHI-specific’ receptors and that the binding 
of PHI to these membranes may be entirely accounted 
for by the affinity of PHI for the VIP-receptors. 
3.2. Stimulation of cyclic AMP 
Whether the affinity of PHI for these receptors 
reflects its ability to modulate a biological process 
was tested by comparing the effect of PHI and VIP 
on cyclic AMP production in liver membranes 
(table 1) and in isolated intestinal epithelial cells 
(fig.2, left). Indeed, the potency of PHI relative to 
that of VIP was at least as high as that observed in 
the binding experiments, -30-40% in both systems. 
It must also be noticed that the efficacy of PHI, i.e., 
its ability to stimulate maximally the cyclic AMP 
production, was identical to that of VIP (table 1, 
fig.2, left). 
The picture is very different in isolated gastric 
glands (fig.1, right), where a cyclic AMP system 
highly sensitive to secretin and 200-times less sensi- 
tive to VIP has been discovered [3]: PHI was 2-5% 
as potent as secretin and 3-lo-times more potent 
than VIP; the dilution curve did not parallel that of 
secretin or VIP and the efficacy of PHI was -70% of 
that of either peptide. 
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Fig-l. Effect of VIP (o-o) and PHI (o-o) on the bind- 
ing of [ ‘lsI]VIP (upper panels) and [ “‘I]PHI (lower panels) 
to liver (left) and intestinal (right) membranes. Results are 
the means of duplicate determinations. Similar data were 
obtained in 6 expt. (upper left) and in 2 expt. (other panels). 
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Fig.2. Effect of VIP (o-o), PHI (o-o) and secretin 
(A-A) on the cyclic AMP accumulation in isolated intes- 
tinal epithelii cells (left), fat cells (center) and gastric glands 
from the fundus (right). Each point is the mean of 2 expt., 
each performed in triplicate. 
Table 1 






VIP equivalent (%) 
1 l/2 
50 2 14 32?4 
29* 3 33 i 2.5 
l/4 
26 f 3 
31 *6 
Results are expressed as VIP equivalent, in percent, and are 
the means * SEM of 3 determinations. Initial concentrations 
of PHI were 3 . lo-” M and 4 . lo-” M in expt. 1 and 2, 
respectively and corresponded to the PHI-concentrations that 
display that maximal effect obtainable with either VIP or 
PHI 
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In isolated fat cell preparations previously referred 
to as ‘type II’ [7] that contain both VIP and secretin 
receptors and that, accordingly, are equally sensitive 
to VIP and secretin (fig.2, center), PHI was 10-15s 
as potent as VIP or secretin, with the same efficacy 
as either peptide (fig.2, center). 
4. Discussion 
These data clearly demonstrate that a new peptide, 
PHI, is almost as active as VIP in tissue preparations 
which are responsive to VIP: indeed, only 2.5-S-times 
higher concentrations of PHI were necessary to 
observe the same effect as with VIP. It is also clear 
that, in the tissues tested, this activity is mediated by 
a common receptor which is shared by VIP and PHI 
and which has been first described as VIP-receptor 
[ 1 ,161. The secretin-like action of PHI in gastric 
glands is probably mediated by the secretin receptors 
as suggested by the high doses of PHI necessary to 
obtain a response (fig.2, right) and by the absence of 
additivity between the effects of PHI and secretin 
(not shown). In fat cells that contain both VIP and 
secretin receptors, the action of PHI is close to that 
which would be expected if only VIP receptors were 
present. 
PHI is a novel 27 amino acid intestinal peptide 
which, in spite of some chemical [6] and biological 
(as shown here) similarities with VIP and secretin, 
displays many structural differences from all other 
peptides hitherto isolated [ 61. The physiological 
status of this peptide is, so far, largely speculative. 
The relatively high concentrations necessary to 
obtain a response in gastric glands is not in favour 
of a physiological role of PHI in stomach, at least 
through its cyclic AMP-mediated secretin-like action. 
However, it must be kept in mind that all peptides 
used were of porcine origin, while the tissue prepara- 
tions originate from the rat; the picture might be dif- 
ferent in an homogeneous model. This holds true 
for the VIP-like effect of PHI; but, in any case, the 
close similarity between the potency of PHI and VIP 
observed in VIP-sensitive target tissue cannot be con- 
sidered as the result of a simple cross-reaction with 
no physiological meaning. On the contrary, it allows 
to speculate that VIP and PHI may regulate the same 
physiological events via a common receptor-cyclic 
AMP system through different neural and/or endo- 
crine pathways. On the other hand, whether PHI has, 
apart from its VIP and secretin-like effects, specific 
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biological action(s) will await further in vivo and 
in vitro studies, and particularly the search for even- 
tual specific PHI-receptors. 
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